According to Golikova, in addition to the SRCEM, which works together with the Ministry of Defense, the vaccine is also being developed rapidly at the SSC Vector of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare and Serum at the St. Petersburg Institute for Vaccines and Serums of the FMBA of Russia.
Clinical trials of the drug at the Institute of Gamalei are held in June-August, and the Vector according to the plan is only slightly behind - the clinical trials are planned until September, in which the state registration of the vaccine is planned. Immediately after this, its launch in industrial production is scheduled.
According to the Deputy Prime Minister, the FMBA Vaccine and Serum Institute has planned clinical trials of its development from September to December, with a planned launch in December.
As the director of the Center, academician of the Russian Academy of Sciences Alexander Gunzburg told the agency, the center together with the Ministry of Defense is developing a vector vaccine based on adenovirus DNA, in which the SARS-CoV-2 coronavirus gene is integrated.
The vaccine has already been unofficially tested on developer volunteers. It is noted that they all feel good and have immunity.
Earlier, the Ministry of Defense reported that a new vaccine for coronavirus is planned to be tested on the first group of volunteers who were selected from different units across the country. In total, 50 military personnel were selected to study the effectiveness of the new drug.
Meanwhile, in the United States, army doctors specializing in testing various vaccines for the new coronavirus are creating their own medicine, which should become universal among the means of combating other probable strains of infection. Currently, army experts are studying several vaccines - from the companies Moderna, AstraZeneca and Johnson & Johnson.